Holen Sie sich die Stockscreener-App
1.62
9.46%
0.14
Handel nachbörslich:
1.62
Schlusskurs vom Vortag:
$1.48
Offen:
$1.51
24-Stunden-Volumen:
2.15M
Relative Volume:
2.38
Marktkapitalisierung:
$85.44M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-151.16M
KGV:
-0.5063
EPS:
-3.2
Netto-Cashflow:
$-130.08M
1W Leistung:
+11.72%
1M Leistung:
+33.88%
6M Leistung:
-76.45%
1J Leistung:
-87.69%
1-Tages-Spanne:
$1.51
$1.67
1-Wochen-Bereich:
$1.435
$2.05
52-Wochen-Spanne:
$1.19
$17.82
Alx Oncology Holdings Inc Stock (ALXO) Company Profile
Firmenname
Alx Oncology Holdings Inc
Sektor
Branche
Telefon
650-466-7125
Adresse
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Vergleichen Sie ALXO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALXO
Alx Oncology Holdings Inc
|
1.62 | 85.44M | 0 | -151.16M | -130.08M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-08 | Hochstufung | Jefferies | Hold → Buy |
| 2021-12-22 | Herabstufung | Jefferies | Buy → Hold |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-05-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-06 | Eingeleitet | UBS | Buy |
| 2021-02-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-08-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-08-11 | Eingeleitet | Credit Suisse | Outperform |
| 2020-08-11 | Eingeleitet | Jefferies | Buy |
| 2020-08-11 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Alx Oncology Holdings Inc Aktie (ALXO) Neueste Nachrichten
ALX Oncology’s (ALXO) Overweight Rating Reiterated at Cantor Fitzgerald - Defense World
ALX Oncology’s (ALXO) “Buy” Rating Reiterated at HC Wainwright - Defense World
Alx Oncology Holdings Inc (ALXO) Is On The Launchpad, Waiting For Long-Term Buyers. - Stocks Register
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Shares Sold by Charles Schwab Investment Management Inc. - Defense World
ALX Oncology stock falls on Jefferies downgrade (ALXO:NASDAQ) - Seeking Alpha
Alx Oncology shares down in pre-market as Jefferies downgrades stock to 'hold' - Investing.com Canada
Jefferies Financial Group Downgrades ALX Oncology (NASDAQ:ALXO) to Hold - MarketBeat
Early-Onset Cancer Trends Spark Interest in Promising Oncology Pipelines - Baystreet.ca
ALX Oncology (NASDAQ:ALXO) Earns "Overweight" Rating from Cantor Fitzgerald - MarketBeat
HC Wainwright Reiterates Buy Rating for ALX Oncology (NASDAQ:ALXO) - MarketBeat
ALX Oncology to Present Updated Results from Phase 2 - GlobeNewswire
ALX Oncology to Present Key Phase 2 Gastric Cancer Trial Data at ASCO GI 2025 Symposium - StockTitan
ALX Oncology Highlights Promising Trial Results - MSN
ALX Oncology to Host Webcast on December 17 Featuring Phase 1b/2 Trial Data for Evorpacept in Metastatic Breast Cancer - Nasdaq
ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024 - The Manila Times
ALX Oncology Sets Key Data Review: Evorpacept Breast Cancer Trial Results From SABCS 2024 - StockTitan
Fmr LLC Sells 1,949,890 Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) - MarketBeat
ALX Oncology Announces New Data Demonstrating Evorpacept in - GlobeNewswire
ALX Oncology's Evorpacept Shows 55.6% Response Rate in HER2+ Breast Cancer Trial - StockTitan
ALXO (ALX Oncology Holdings) Enterprise Value : $-43.27 Mil (As of Dec. 07, 2024) - GuruFocus.com
Insider Buying: Rekha Hemrajani Acquires 30,000 Shares of ALX On - GuruFocus.com
ALXO (ALX Oncology Holdings) Price-to-Operating-Cash-Flow : (As of Dec. 03, 2024) - GuruFocus.com
ALX Oncology shares jump 9% after Jefferies upgrade - MSN
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives $12.50 Average Target Price from Brokerages - Defense World
Brokerages Set ALX Oncology Holdings Inc. (NASDAQ:ALXO) PT at $12.50 - Defense World
Financial Review: Inventiva (NASDAQ:IVA) & ALX Oncology (NASDAQ:ALXO) - Defense World
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
3 US Penny Stocks With Market Caps Over $30M To Consider - Simply Wall St
ALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
ALX Oncology CEO to Present at Piper Sandler Healthcare Conference | ALXO Stock News - StockTitan
GSA Capital Partners LLP Invests $88,000 in ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
Contrasting ALX Oncology (NASDAQ:ALXO) & Viracta Therapeutics (NASDAQ:VIRX) - Defense World
ALX Oncology Holdings (ALXO) Loses -27.11% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Short Interest Update - Defense World
ALX Oncology FY2024 EPS Forecast Raised by Cantor Fitzgerald - Defense World
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Sees Significant Decrease in Short Interest - MarketBeat
Brokers Set Expectations for ALX Oncology FY2024 Earnings - MarketBeat
Former Mirati CMO Alan Sandler joins ALX Oncology - The Pharma Letter
Data-Based Insights About XBP Europe Holdings Inc (XBP) - Stocks Register
New Outlook On Celsius Holdings Inc - Stocks Register
ALX Oncology Strengthens Leadership with Key Appointment - TipRanks
ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer - NRToday.com
ALX Oncology Appoints Former Mirati & Genentech Exec as Chief Medical Officer | ALXO Stock News - StockTitan
ALX Oncology Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Cantor Fitzgerald Reiterates Overweight Rating for ALX Oncology (NASDAQ:ALXO) - Defense World
ALXO stock touches 52-week low at $1.31 amid market challenges - Investing.com
FMR LLC's Strategic Reduction in ALX Oncology Holdings Inc Shares - GuruFocus.com
ALX Oncology's (ALXO) Overweight Rating Reaffirmed at Cantor Fitzgerald - MarketBeat
Brokers Issue Forecasts for ALX Oncology FY2028 Earnings - MarketBeat
ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Finanzdaten der Alx Oncology Holdings Inc-Aktie (ALXO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Alx Oncology Holdings Inc-Aktie (ALXO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Pinto Shelly | SVP, FINANCE AND CAO |
Aug 14 '24 |
Sale |
2.58 |
564 |
1,455 |
91,549 |
| Randolph Sophia | CHIEF MEDICAL OFFICER |
Aug 14 '24 |
Sale |
2.58 |
1,365 |
3,522 |
325,711 |
| Pons Jaume | PRESIDENT & CSO |
Aug 14 '24 |
Sale |
2.58 |
1,937 |
4,997 |
591,510 |
| Pons Jaume | PRESIDENT & CSO |
Jul 11 '24 |
Option Exercise |
0.99 |
20,000 |
19,800 |
613,447 |
| Pons Jaume | PRESIDENT & CSO |
Jul 11 '24 |
Sale |
7.90 |
20,000 |
158,076 |
593,447 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Jul 05 '24 |
Sale |
5.50 |
1,823 |
10,025 |
92,113 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Jul 01 '24 |
Sale |
5.82 |
1,373 |
7,989 |
93,936 |
| Randolph Sophia | CHIEF MEDICAL OFFICER |
Jul 01 '24 |
Sale |
5.82 |
3,273 |
19,045 |
327,076 |
| Pons Jaume | PRESIDENT & CSO |
Jul 01 '24 |
Sale |
5.82 |
10,758 |
62,599 |
593,447 |
| GARCIA PETER S | CHIEF FINANCIAL OFFICER |
Jun 13 '24 |
Buy |
8.53 |
12,000 |
102,338 |
122,348 |
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):